Page 17 - B Cell News Today

A recent study investigates samples solated from unexposed individuals pre-pandemic to determine the presence of pre-existing SARS-CoV-2 B-cell immunity.

Researchers examined the memory B cell repertoire of individuals immunized with three doses of mRNA-based COVID-19 vaccine.

A recent study posted to the medRxiv* preprint server investigated the risk of severe/fatal coronavirus disease 2019 (COVID-19) in patients treated with immunosuppressants for inflammatory rheumatic diseases (IRD).

For at least six months after COVID-19 vaccination, antibodies produced by immune cells become steadily more formidable and more precisely targeted against the virus that causes COVID-19, according to a study of the antibody response to the Pfizer-BioNTech vaccine by researchers at Washington University School of Medicine in St. Louis.

A new study created stable cell lines capable of producing different genotypes of the hepatitis B virus (HBV), advancing understanding of each type's distinct virological features, treatment responses, and infectivity that could lead to new therapies against a virus infecting humans as far back as 4,500 years ago.

In a recent research article published in the journal of Science Immunology, a team of researchers from Japan performed longitudinal analysis on the cellular composition of receptor-binding domain (RBD) memory B cell subsets and its antibody binding and neutralizing activity against the Beta, Delta, and Omicron variants following the second dose of a messenger ribonucleic acid (mRNA) vaccine.

A team of researchers recently captured memory B cells from a cohort of SARS-CoV-2 convalescent or mRNA-vaccinated individuals to study the evolution of B cell-mediated antibody responses to the N-terminal domain in humans.

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

THURSDAY, Jan. 27, 2022 (HealthDay News) -- An initial surge in antibody levels against the Omicron variant after a booster dose of the Moderna COVID vaccine wanes within six months,

THURSDAY, Jan. 27, 2022 (HealthDay News) -- An initial surge in antibody levels against the Omicron variant after a booster dose of the Moderna COVID vaccine wanes within six months,